On June 29, 2021 Boston Children’s Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, reported that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement enables Boston Children’s and ElevateBio to form multiple cell and gene therapy companies together; provides Boston Children’s researchers access to ElevateBio’s core-enabling technologies, manufacturing, and leading expertise to advance their programs; and will guarantee Boston Children’s researchers dedicated viral-vector manufacturing space at ElevateBio BaseCamp, ElevateBio’s centralized world-class research and development manufacturing center. In addition, under this agreement, ElevateBio will commit to sponsored research agreements with Boston Children’s investigators as part of the company formation process.
"At Boston Children’s Hospital, we are proud of the foundation we’ve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio – a company so well-positioned to change the face of cell and gene therapy forever – is a natural fit into our overall vision," said David Williams, M.D., formerly Senior Vice President for Research and Chief Scientific Officer, currently Chief of Hematology / Oncology, Boston Children’s Hospital. "Using ElevateBio’s world-class enabling technologies, this alliance will help catalyze the science being conducted in the labs across Boston Children’s, moving potential treatments into the clinic and accelerating the development of multiple cell and gene therapy platforms."
"Boston Children’s Hospital is committed to accelerating the translation of our research into treatments that will improve patients’ lives," said Irene Abrams, Vice President of Technology Development and New Ventures, Boston Children’s Hospital. "and this relationship with ElevateBio is a key part of that effort."
"At ElevateBio, we have built unique end-to-end capabilities that leverage our suite of enabling technologies, technologic know-how, and world-class expertise to advance our own innovative cell and gene therapies as well as accelerate those of industry and academic collaborators," said David Hallal, Chairman and Chief Executive Officer of ElevateBio. "Boston Children’s Hospital has a strong history of innovation in the cell and gene therapy sector through ground-breaking science and spinning out companies to deliver medicines to patients. Through this collaboration, we’re excited to work with the team at Boston Children’s to form new companies, the first of which we’ve identified and will announce later this year, and also enable access to our cutting-edge viral vector manufacturing facilities that will help Boston Children’s researchers move their therapies through development more efficiently."